Announcements Trials

Browse Landscape

Phase

Status

Completed 51 Unknown 13 Terminated 9 Active not recruiting 4 Withdrawn 3 Recruiting 3 Approved for marketing 3 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 4 Docetaxel 3 pembrolizumab 2 Nivolumab 2 Etoposide 2 Carboplatin 2 osimertinib 1 icotinib 1 famitinib 1 durvalumab 1 decitabine and cedazuridine drug combination 1 dabrafenib 1 cemiplimab 1 alirocumab 1 aldesleukin 1 Surgical Procedures, Operative 1 Specimen Handling 1 Radiotherapy 1 Radiosurgery 1 Radionuclide Imaging 1 Radiation 1 Prednisone 1 Positron-Emission Tomography 1 Platinum 1 Pemetrexed 1 Panitumumab 1 Paclitaxel 1 Monatide (IMS 3015) 1 Methods 1 Magnetic Resonance Spectroscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Afatinib × Thoracic × Clear all

NCT02470065 2016-01-22

REMNANT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡